Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia

Ayalew Tefferi, Shireen Sirhan, Terra L. Lasho, Susan M. Schwager, Chin Yang Li, David M Dingli, Alexandra P. Wolanskyj, David P. Steensma, Ruben Mesa, D. G. Gilliland

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Polycythaemia vera (PV) is closely associated with both an acquired activating mutation of the JAK2 tyrosine kinase (JAK2V617F) in granulocyte-derived DNA and increased granulocyte polycythaemia rubra vera-1 (PRV-1) expression. In order to explore the correlation between these two biological markers and compare their diagnostic utility, mutation analysis for JAK2V617F and quantitative measurement of granulocyte PRV-1 expression were performed on the same study sample from 100 participants: 38 with PV, 22 with essential thrombocythaemia (ET), 10 with agnogenic myeloid metaplasia (AMM), 19 with secondary polycythaemia (SP) and 11 healthy volunteers. The respective overall (homozygous) JAK2V617F mutational frequencies were 95% (26%), 55% (0%), 30% (0%), 0% and 0%. The corresponding figures for increased PRV-1 expression were 89%, 18%, 20%, 21% and 9%. In patients with either ET or AMM, the likelihood of detecting JAK2V617F was significantly higher in the presence of an increased PRV-1 expression (83% vs. 38%; P = 0.05). Similarly, in patients with PV, homozygous as compared with heterozygous JAK2V617F correlated with higher levels of PRV-1 expression (P = 0.11). The present study suggests an allele dose-dependent effect of JAK2V617F on granulocyte PRV-1 expression. However, compared with the PRV-1 assay, mutation screening for JAK2V617F displayed greater accuracy in distinguishing PV from SP.

Original languageEnglish (US)
Pages (from-to)166-171
Number of pages6
JournalBritish Journal of Haematology
Volume131
Issue number2
DOIs
StatePublished - Oct 2005

Fingerprint

Myeloproliferative Disorders
Polycythemia Vera
Polycythemia
Neutrophils
Mutation
Granulocytes
Essential Thrombocythemia
Primary Myelofibrosis
Protein-Tyrosine Kinases
Healthy Volunteers
Biomarkers
Alleles

Keywords

  • Diagnosis
  • Gene expression
  • Mutation
  • Myeloproliferative
  • Polycythaemia
  • Secondary

ASJC Scopus subject areas

  • Hematology

Cite this

Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. / Tefferi, Ayalew; Sirhan, Shireen; Lasho, Terra L.; Schwager, Susan M.; Li, Chin Yang; Dingli, David M; Wolanskyj, Alexandra P.; Steensma, David P.; Mesa, Ruben; Gilliland, D. G.

In: British Journal of Haematology, Vol. 131, No. 2, 10.2005, p. 166-171.

Research output: Contribution to journalArticle

Tefferi, Ayalew ; Sirhan, Shireen ; Lasho, Terra L. ; Schwager, Susan M. ; Li, Chin Yang ; Dingli, David M ; Wolanskyj, Alexandra P. ; Steensma, David P. ; Mesa, Ruben ; Gilliland, D. G. / Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. In: British Journal of Haematology. 2005 ; Vol. 131, No. 2. pp. 166-171.
@article{53cc8daa4b704cbc85d8b81e55ee8b2d,
title = "Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia",
abstract = "Polycythaemia vera (PV) is closely associated with both an acquired activating mutation of the JAK2 tyrosine kinase (JAK2V617F) in granulocyte-derived DNA and increased granulocyte polycythaemia rubra vera-1 (PRV-1) expression. In order to explore the correlation between these two biological markers and compare their diagnostic utility, mutation analysis for JAK2V617F and quantitative measurement of granulocyte PRV-1 expression were performed on the same study sample from 100 participants: 38 with PV, 22 with essential thrombocythaemia (ET), 10 with agnogenic myeloid metaplasia (AMM), 19 with secondary polycythaemia (SP) and 11 healthy volunteers. The respective overall (homozygous) JAK2V617F mutational frequencies were 95{\%} (26{\%}), 55{\%} (0{\%}), 30{\%} (0{\%}), 0{\%} and 0{\%}. The corresponding figures for increased PRV-1 expression were 89{\%}, 18{\%}, 20{\%}, 21{\%} and 9{\%}. In patients with either ET or AMM, the likelihood of detecting JAK2V617F was significantly higher in the presence of an increased PRV-1 expression (83{\%} vs. 38{\%}; P = 0.05). Similarly, in patients with PV, homozygous as compared with heterozygous JAK2V617F correlated with higher levels of PRV-1 expression (P = 0.11). The present study suggests an allele dose-dependent effect of JAK2V617F on granulocyte PRV-1 expression. However, compared with the PRV-1 assay, mutation screening for JAK2V617F displayed greater accuracy in distinguishing PV from SP.",
keywords = "Diagnosis, Gene expression, Mutation, Myeloproliferative, Polycythaemia, Secondary",
author = "Ayalew Tefferi and Shireen Sirhan and Lasho, {Terra L.} and Schwager, {Susan M.} and Li, {Chin Yang} and Dingli, {David M} and Wolanskyj, {Alexandra P.} and Steensma, {David P.} and Ruben Mesa and Gilliland, {D. G.}",
year = "2005",
month = "10",
doi = "10.1111/j.1365-2141.2005.05743.x",
language = "English (US)",
volume = "131",
pages = "166--171",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia

AU - Tefferi, Ayalew

AU - Sirhan, Shireen

AU - Lasho, Terra L.

AU - Schwager, Susan M.

AU - Li, Chin Yang

AU - Dingli, David M

AU - Wolanskyj, Alexandra P.

AU - Steensma, David P.

AU - Mesa, Ruben

AU - Gilliland, D. G.

PY - 2005/10

Y1 - 2005/10

N2 - Polycythaemia vera (PV) is closely associated with both an acquired activating mutation of the JAK2 tyrosine kinase (JAK2V617F) in granulocyte-derived DNA and increased granulocyte polycythaemia rubra vera-1 (PRV-1) expression. In order to explore the correlation between these two biological markers and compare their diagnostic utility, mutation analysis for JAK2V617F and quantitative measurement of granulocyte PRV-1 expression were performed on the same study sample from 100 participants: 38 with PV, 22 with essential thrombocythaemia (ET), 10 with agnogenic myeloid metaplasia (AMM), 19 with secondary polycythaemia (SP) and 11 healthy volunteers. The respective overall (homozygous) JAK2V617F mutational frequencies were 95% (26%), 55% (0%), 30% (0%), 0% and 0%. The corresponding figures for increased PRV-1 expression were 89%, 18%, 20%, 21% and 9%. In patients with either ET or AMM, the likelihood of detecting JAK2V617F was significantly higher in the presence of an increased PRV-1 expression (83% vs. 38%; P = 0.05). Similarly, in patients with PV, homozygous as compared with heterozygous JAK2V617F correlated with higher levels of PRV-1 expression (P = 0.11). The present study suggests an allele dose-dependent effect of JAK2V617F on granulocyte PRV-1 expression. However, compared with the PRV-1 assay, mutation screening for JAK2V617F displayed greater accuracy in distinguishing PV from SP.

AB - Polycythaemia vera (PV) is closely associated with both an acquired activating mutation of the JAK2 tyrosine kinase (JAK2V617F) in granulocyte-derived DNA and increased granulocyte polycythaemia rubra vera-1 (PRV-1) expression. In order to explore the correlation between these two biological markers and compare their diagnostic utility, mutation analysis for JAK2V617F and quantitative measurement of granulocyte PRV-1 expression were performed on the same study sample from 100 participants: 38 with PV, 22 with essential thrombocythaemia (ET), 10 with agnogenic myeloid metaplasia (AMM), 19 with secondary polycythaemia (SP) and 11 healthy volunteers. The respective overall (homozygous) JAK2V617F mutational frequencies were 95% (26%), 55% (0%), 30% (0%), 0% and 0%. The corresponding figures for increased PRV-1 expression were 89%, 18%, 20%, 21% and 9%. In patients with either ET or AMM, the likelihood of detecting JAK2V617F was significantly higher in the presence of an increased PRV-1 expression (83% vs. 38%; P = 0.05). Similarly, in patients with PV, homozygous as compared with heterozygous JAK2V617F correlated with higher levels of PRV-1 expression (P = 0.11). The present study suggests an allele dose-dependent effect of JAK2V617F on granulocyte PRV-1 expression. However, compared with the PRV-1 assay, mutation screening for JAK2V617F displayed greater accuracy in distinguishing PV from SP.

KW - Diagnosis

KW - Gene expression

KW - Mutation

KW - Myeloproliferative

KW - Polycythaemia

KW - Secondary

UR - http://www.scopus.com/inward/record.url?scp=32944477304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944477304&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2005.05743.x

DO - 10.1111/j.1365-2141.2005.05743.x

M3 - Article

VL - 131

SP - 166

EP - 171

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -